Recognizing the immune-evasive nature of XBB-derived lineages, both the Vaccines and Related Biological Products Advisory Committee (VRBPAC) and Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) recommended a mono-antigen composition for the 2023–2024 COVID-19 vaccine formulation, focusing on the Omicron XBB.1.5 subvariant spike protein [11,12]. This evidence concerns the gene CHMP5 and COVID-19.